Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 6,080 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matched control Clear all
Recruiting No phase listed Observational

Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise

NCT05025774
View directory record Official record
Conditions
Chronic Lung Disease, Chronic Obstructive Pulmonary Disease, Acute Lymphoblastic Leukemia, Heart Transplant
Interventions
Physical activity
Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
8 Years to 25 Years
Enrollment
90 participants
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 30, 2026, 8:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Perfusion in Pantothenate Kinase-associated Neurodegeneration (PKAN)

NCT01838018
View directory record Official record
Conditions
Pantothenate Kinase-associated Neurodegeneration (PKAN)
Interventions
Not listed
Lead sponsor
Susan J. Hayflick
Other
Eligibility
7 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

NCT04867980
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ACP-196, Moxifloxacin 400 mg, Placebo
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 30, 2026, 8:27 PM EDT
Not listed No phase listed Observational

Monitoring Necrotizing Enterocolitis in Premature Infants

NCT01287559
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
Not listed
Lead sponsor
Spectros Corporation
Industry
Eligibility
Up to 6 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Irvine, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2011 · Synced Oct 30, 2026, 8:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation and Validation of a Multimodal Brain Function Biomarker With NPC

NCT04074486
View directory record Official record
Conditions
Brain Injuries, Concussion, Mild, Concussion, Brain, Near Point Convergence, Concussion, Intermediate
Interventions
BrainScope Ahead 300iP-O, SCAT5, Near Point Convergence
Device · Diagnostic Test
Lead sponsor
BrainScope Company, Inc.
Industry
Eligibility
13 Years to 50 Years
Enrollment
1,318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
6
States / cities
Fayetteville, Arkansas • Storrs, Connecticut • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 2 Interventional Results available

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

NCT05162586
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Torrance, California • Brandon, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 3 Interventional Results available

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

NCT00603291
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 30, 2026, 8:27 PM EDT
Not listed Phase 3 Interventional

A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer

NCT02773524
View directory record Official record
Conditions
Gastro-Oesophageal Cancer
Interventions
Regorafenib, Placebo
Drug · Other
Lead sponsor
Australasian Gastro-Intestinal Trials Group
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • Urbana, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 30, 2026, 8:27 PM EDT
Not yet recruiting Phase 2 Interventional

A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant

NCT07613359
View directory record Official record
Conditions
Antibody-Mediated Rejection (AMR)
Interventions
Mezagitamab, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 30, 2026, 8:27 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

NCT07496450
View directory record Official record
Conditions
Influenza
Interventions
mRNA-1018-H5, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4,050 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
10
States / cities
San Bernardino, California • Savannah, Georgia • Meridian, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 30, 2026, 8:27 PM EDT
Not listed Phase 2 Interventional

Treating Cocaine Abuse: A Behavioral Approach

NCT01822327
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Contingency Management
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 2, 2013 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps

NCT03960580
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
OPN-375
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
Birmingham, Alabama • Folsom, California • La Mesa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 30, 2026, 8:27 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Feasibility of ADRCs (Adipose Derived Regenerative Cells) in Patients With Grade II Hamstring Tears

NCT02045888
View directory record Official record
Conditions
Muscle Tear
Interventions
ADRCs prepared by investigational Celution Device, Placebo
Device · Biological
Lead sponsor
Cytori Therapeutics
Industry
Eligibility
20 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427

NCT04630067
View directory record Official record
Conditions
Heart Failure
Interventions
AZD3427, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
10
States / cities
Little Rock, Arkansas • Glendale, California • Daytona Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of Icosabutate in Fatty Liver Disease

NCT04052516
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
Icosabutate, Placebo
Drug
Lead sponsor
NorthSea Therapeutics B.V.
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
38
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function

NCT05711381
View directory record Official record
Conditions
Renal Impairment
Interventions
HM15912
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Tustin, California • Miami, Florida • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 30, 2026, 8:27 PM EDT
Recruiting No phase listed Observational

DELINEATE-Prospective

NCT07197736
View directory record Official record
Conditions
Valve Disease, Aortic, Mitral Regurgitation (MR), Aortic Stenosis, Valvular Heart Disease, Tricuspid Regurgitation (TR), Aortic Regurgitation
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 30, 2026, 8:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment and Rehabilitation of Cognitive Impairments in Pediatric Survivors of Cancer

NCT00490334
View directory record Official record
Conditions
Neoplasms
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
9 Years to 16 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 30, 2026, 8:27 PM EDT
Recruiting No phase listed Observational

Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure

NCT07209098
View directory record Official record
Conditions
Heart Failure and Reduced Ejection Fraction, NYHA Class III Heart Failure
Interventions
Cardiac Contractility Modulation (CCM)
Device
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
4,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 30, 2026, 8:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lateral Neck Flexor Endurance and Hyperlaxity

NCT04770987
View directory record Official record
Conditions
Physical Endurance, Hypermobility, Joint, Muscular Weakness
Interventions
lateral neck flexor endurance test
Other
Lead sponsor
University of Hartford
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
West Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 2 Interventional Results available

Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer

NCT01936363
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Pimasertib once daily, Pimasertib placebo, SAR245409 placebo, SAR245409, Pimasertib twice daily
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
17
States / cities
Augusta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults

NCT02142504
View directory record Official record
Conditions
Norovirus Prevention
Interventions
Norovirus Bivalent VLP Vaccine, Placebo (Saline)
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
454 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 30, 2026, 8:27 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

NCT06878404
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Icotrokinra, Placebo, Active reference comparator
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Jonesboro, Arkansas • DeBary, Florida • Plantation, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 8:27 PM EDT
Completed Phase 1 Interventional

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

NCT03479892
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC0194-0499, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
22 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 30, 2026, 8:27 PM EDT